Cell invasion of highly metastatic MTLn3 cancer cells is dependent on phospholipase D2 (PLD2) and janus kinase 3 (JAK3)

Karen M. Henkels, Terry Farkaly, Madhu Mahankali, Jeffrey E. Segall, Julian Gomez-Cambronero

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

MTLn3 cells are highly invasive breast adenoacarcinoma cells. The relative level of the epidermal-growth-factor-stimulated invasion of this cell line is greater than two other breast cancer cell lines (MDA-MB-231 and MCF-7) and one non-small cell lung cancer cell line (H1299). We have determined that the mechanism of cancer cell invasion involves the presence of an enzymatically active phospholipase D (PLD), with the PLD2 isoform being more relevant than PLD1. PLD2 silencing abrogated invasion, whereas ectopic expression of PLD2 augmented cell invasion in all four cell lines, with an efficacy (MTLn3 ± MDA-MB-231 > H1299 ± MCF-7) that correlated well with their abilities to invade Matrigel in vitro. We also report that PLD2 is under the control of Janus kinase 3 (JAK3), with the kinase phosphorylating PLD2 at the Y415 residue, thus enabling its activation. Y415 is located downstream of a PH domain and upstream of the catalytic HKD-1 domain of PLD2. JAK3 knockdown abrogated lipase activity and epidermal-growth-factor-stimulated cell invasion directly. For the purposes of activating PLD2 for cell invasion, JAK3 operates via an alternative pathway that is independent of STAT, at least in MTLn3 cells. We also consistently found that JAK3 and PLD2 pathways are utilized at the maximum efficiency (phosphorylation and activity) in highly invasive MTLn3 cells versus a relatively low utilization in the less invasive MCF-7 cell line. In summary, a high level of cell invasiveness of cancer cells can be explained for the first time by combined high JAK3/PLD2 phosphorylation and activity involving PLD2's Y415 residue, which might constitute a novel target to inhibit cancer cell invasion.

Original languageEnglish (US)
Pages (from-to)850-862
Number of pages13
JournalJournal of Molecular Biology
Volume408
Issue number5
DOIs
StatePublished - May 20 2011

Fingerprint

Janus Kinase 3
Neoplasms
Cell Line
Epidermal Growth Factor
phospholipase D2
Phosphorylation
Phospholipase D
MCF-7 Cells
Lipase
Non-Small Cell Lung Carcinoma

Keywords

  • DMEM
  • Dulbecco's modified Eagle's medium
  • EGF
  • epidermal growth factor
  • FBS
  • fetal bovine serum
  • FITC
  • fluorescein isothiocyanate
  • JAK3
  • Janus kinase 3
  • PA
  • phosphatidic acid
  • phospholipase D
  • PLD
  • SEM
  • SLB
  • special lysis buffer
  • standard error of the mean

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Cell invasion of highly metastatic MTLn3 cancer cells is dependent on phospholipase D2 (PLD2) and janus kinase 3 (JAK3). / Henkels, Karen M.; Farkaly, Terry; Mahankali, Madhu; Segall, Jeffrey E.; Gomez-Cambronero, Julian.

In: Journal of Molecular Biology, Vol. 408, No. 5, 20.05.2011, p. 850-862.

Research output: Contribution to journalArticle

Henkels, Karen M. ; Farkaly, Terry ; Mahankali, Madhu ; Segall, Jeffrey E. ; Gomez-Cambronero, Julian. / Cell invasion of highly metastatic MTLn3 cancer cells is dependent on phospholipase D2 (PLD2) and janus kinase 3 (JAK3). In: Journal of Molecular Biology. 2011 ; Vol. 408, No. 5. pp. 850-862.
@article{af2fa9c2a50a4c4bb457ab54bc45645d,
title = "Cell invasion of highly metastatic MTLn3 cancer cells is dependent on phospholipase D2 (PLD2) and janus kinase 3 (JAK3)",
abstract = "MTLn3 cells are highly invasive breast adenoacarcinoma cells. The relative level of the epidermal-growth-factor-stimulated invasion of this cell line is greater than two other breast cancer cell lines (MDA-MB-231 and MCF-7) and one non-small cell lung cancer cell line (H1299). We have determined that the mechanism of cancer cell invasion involves the presence of an enzymatically active phospholipase D (PLD), with the PLD2 isoform being more relevant than PLD1. PLD2 silencing abrogated invasion, whereas ectopic expression of PLD2 augmented cell invasion in all four cell lines, with an efficacy (MTLn3 ± MDA-MB-231 > H1299 ± MCF-7) that correlated well with their abilities to invade Matrigel in vitro. We also report that PLD2 is under the control of Janus kinase 3 (JAK3), with the kinase phosphorylating PLD2 at the Y415 residue, thus enabling its activation. Y415 is located downstream of a PH domain and upstream of the catalytic HKD-1 domain of PLD2. JAK3 knockdown abrogated lipase activity and epidermal-growth-factor-stimulated cell invasion directly. For the purposes of activating PLD2 for cell invasion, JAK3 operates via an alternative pathway that is independent of STAT, at least in MTLn3 cells. We also consistently found that JAK3 and PLD2 pathways are utilized at the maximum efficiency (phosphorylation and activity) in highly invasive MTLn3 cells versus a relatively low utilization in the less invasive MCF-7 cell line. In summary, a high level of cell invasiveness of cancer cells can be explained for the first time by combined high JAK3/PLD2 phosphorylation and activity involving PLD2's Y415 residue, which might constitute a novel target to inhibit cancer cell invasion.",
keywords = "DMEM, Dulbecco's modified Eagle's medium, EGF, epidermal growth factor, FBS, fetal bovine serum, FITC, fluorescein isothiocyanate, JAK3, Janus kinase 3, PA, phosphatidic acid, phospholipase D, PLD, SEM, SLB, special lysis buffer, standard error of the mean",
author = "Henkels, {Karen M.} and Terry Farkaly and Madhu Mahankali and Segall, {Jeffrey E.} and Julian Gomez-Cambronero",
year = "2011",
month = "5",
day = "20",
doi = "10.1016/j.jmb.2011.03.017",
language = "English (US)",
volume = "408",
pages = "850--862",
journal = "Journal of Molecular Biology",
issn = "0022-2836",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Cell invasion of highly metastatic MTLn3 cancer cells is dependent on phospholipase D2 (PLD2) and janus kinase 3 (JAK3)

AU - Henkels, Karen M.

AU - Farkaly, Terry

AU - Mahankali, Madhu

AU - Segall, Jeffrey E.

AU - Gomez-Cambronero, Julian

PY - 2011/5/20

Y1 - 2011/5/20

N2 - MTLn3 cells are highly invasive breast adenoacarcinoma cells. The relative level of the epidermal-growth-factor-stimulated invasion of this cell line is greater than two other breast cancer cell lines (MDA-MB-231 and MCF-7) and one non-small cell lung cancer cell line (H1299). We have determined that the mechanism of cancer cell invasion involves the presence of an enzymatically active phospholipase D (PLD), with the PLD2 isoform being more relevant than PLD1. PLD2 silencing abrogated invasion, whereas ectopic expression of PLD2 augmented cell invasion in all four cell lines, with an efficacy (MTLn3 ± MDA-MB-231 > H1299 ± MCF-7) that correlated well with their abilities to invade Matrigel in vitro. We also report that PLD2 is under the control of Janus kinase 3 (JAK3), with the kinase phosphorylating PLD2 at the Y415 residue, thus enabling its activation. Y415 is located downstream of a PH domain and upstream of the catalytic HKD-1 domain of PLD2. JAK3 knockdown abrogated lipase activity and epidermal-growth-factor-stimulated cell invasion directly. For the purposes of activating PLD2 for cell invasion, JAK3 operates via an alternative pathway that is independent of STAT, at least in MTLn3 cells. We also consistently found that JAK3 and PLD2 pathways are utilized at the maximum efficiency (phosphorylation and activity) in highly invasive MTLn3 cells versus a relatively low utilization in the less invasive MCF-7 cell line. In summary, a high level of cell invasiveness of cancer cells can be explained for the first time by combined high JAK3/PLD2 phosphorylation and activity involving PLD2's Y415 residue, which might constitute a novel target to inhibit cancer cell invasion.

AB - MTLn3 cells are highly invasive breast adenoacarcinoma cells. The relative level of the epidermal-growth-factor-stimulated invasion of this cell line is greater than two other breast cancer cell lines (MDA-MB-231 and MCF-7) and one non-small cell lung cancer cell line (H1299). We have determined that the mechanism of cancer cell invasion involves the presence of an enzymatically active phospholipase D (PLD), with the PLD2 isoform being more relevant than PLD1. PLD2 silencing abrogated invasion, whereas ectopic expression of PLD2 augmented cell invasion in all four cell lines, with an efficacy (MTLn3 ± MDA-MB-231 > H1299 ± MCF-7) that correlated well with their abilities to invade Matrigel in vitro. We also report that PLD2 is under the control of Janus kinase 3 (JAK3), with the kinase phosphorylating PLD2 at the Y415 residue, thus enabling its activation. Y415 is located downstream of a PH domain and upstream of the catalytic HKD-1 domain of PLD2. JAK3 knockdown abrogated lipase activity and epidermal-growth-factor-stimulated cell invasion directly. For the purposes of activating PLD2 for cell invasion, JAK3 operates via an alternative pathway that is independent of STAT, at least in MTLn3 cells. We also consistently found that JAK3 and PLD2 pathways are utilized at the maximum efficiency (phosphorylation and activity) in highly invasive MTLn3 cells versus a relatively low utilization in the less invasive MCF-7 cell line. In summary, a high level of cell invasiveness of cancer cells can be explained for the first time by combined high JAK3/PLD2 phosphorylation and activity involving PLD2's Y415 residue, which might constitute a novel target to inhibit cancer cell invasion.

KW - DMEM

KW - Dulbecco's modified Eagle's medium

KW - EGF

KW - epidermal growth factor

KW - FBS

KW - fetal bovine serum

KW - FITC

KW - fluorescein isothiocyanate

KW - JAK3

KW - Janus kinase 3

KW - PA

KW - phosphatidic acid

KW - phospholipase D

KW - PLD

KW - SEM

KW - SLB

KW - special lysis buffer

KW - standard error of the mean

UR - http://www.scopus.com/inward/record.url?scp=79955480000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955480000&partnerID=8YFLogxK

U2 - 10.1016/j.jmb.2011.03.017

DO - 10.1016/j.jmb.2011.03.017

M3 - Article

C2 - 21414324

AN - SCOPUS:79955480000

VL - 408

SP - 850

EP - 862

JO - Journal of Molecular Biology

JF - Journal of Molecular Biology

SN - 0022-2836

IS - 5

ER -